Mineralys Therapeutics (MLYS) Competitors $12.34 +0.51 (+4.31%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MLYS vs. AMRX, LBPH, LGND, GERN, NAMS, IDYA, CNTA, WVE, AKRO, and MIRMShould you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Amneal Pharmaceuticals (AMRX), Longboard Pharmaceuticals (LBPH), Ligand Pharmaceuticals (LGND), Geron (GERN), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Wave Life Sciences (WVE), Akero Therapeutics (AKRO), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical preparations" industry. Mineralys Therapeutics vs. Amneal Pharmaceuticals Longboard Pharmaceuticals Ligand Pharmaceuticals Geron NewAmsterdam Pharma IDEAYA Biosciences Centessa Pharmaceuticals Wave Life Sciences Akero Therapeutics Mirum Pharmaceuticals Amneal Pharmaceuticals (NASDAQ:AMRX) and Mineralys Therapeutics (NASDAQ:MLYS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking. Does the MarketBeat Community favor AMRX or MLYS? Amneal Pharmaceuticals received 2 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 94.12% of users gave Amneal Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmneal PharmaceuticalsOutperform Votes1694.12% Underperform Votes15.88%Mineralys TherapeuticsOutperform Votes14100.00% Underperform VotesNo Votes Which has more risk and volatility, AMRX or MLYS? Amneal Pharmaceuticals has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Do analysts rate AMRX or MLYS? Amneal Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 28.53%. Mineralys Therapeutics has a consensus target price of $30.00, indicating a potential upside of 143.11%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Amneal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amneal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor AMRX or MLYS? In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 4 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.15 beat Amneal Pharmaceuticals' score of 0.52 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, AMRX or MLYS? Mineralys Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmneal Pharmaceuticals$2.68B0.90-$83.99M-$0.68-11.44Mineralys TherapeuticsN/AN/A-$71.90M-$3.27-3.77 Do insiders and institutionals hold more shares of AMRX or MLYS? 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is AMRX or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -6.88%. Mineralys Therapeutics' return on equity of -55.92% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amneal Pharmaceuticals-6.88% -346.26% 4.85% Mineralys Therapeutics N/A -55.92%-51.70% SummaryMineralys Therapeutics beats Amneal Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLYS vs. The Competition Export to ExcelMetricMineralys TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$588.77M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-3.7710.5991.3417.19Price / SalesN/A195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book2.105.104.794.78Net Income-$71.90M$151.51M$120.07M$225.60M7 Day Performance3.70%-2.14%-1.90%-1.24%1 Month Performance3.96%-3.13%11.43%3.06%1 Year Performance65.19%11.51%30.59%16.50% Mineralys Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLYSMineralys Therapeutics2.7089 of 5 stars$12.34+4.3%$30.00+143.1%+62.4%$588.77MN/A-3.7728News CoveragePositive NewsHigh Trading VolumeAMRXAmneal Pharmaceuticals2.8899 of 5 stars$7.75-1.0%$10.00+29.0%+47.1%$2.40B$2.68B-11.387,700Analyst DowngradeNews CoveragePositive NewsLBPHLongboard Pharmaceuticals0.6607 of 5 stars$59.98+0.0%$59.56-0.7%+986.6%$2.34BN/A-26.9020LGNDLigand Pharmaceuticals4.9816 of 5 stars$122.34+4.6%$147.00+20.2%+65.4%$2.31B$152.42M47.4480Analyst RevisionGERNGeron3.84 of 5 stars$3.81-1.3%$7.15+87.7%+61.6%$2.30B$29.48M-12.06141Short Interest ↓NAMSNewAmsterdam Pharma2.8425 of 5 stars$24.71+0.1%$36.20+46.5%+142.4%$2.28B$33.59M0.0057Insider TradeAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.3209 of 5 stars$26.05+3.4%$53.67+106.0%-23.7%$2.25B$3.92M-10.8180Analyst ForecastCNTACentessa Pharmaceuticals3.0087 of 5 stars$16.75+1.1%$25.83+54.2%+131.0%$2.21B$6.85M-10.8372Insider TradeWVEWave Life Sciences4.8814 of 5 stars$13.45+0.1%$22.22+65.2%+181.5%$2.05B$53.61M-12.22240Positive NewsAKROAkero Therapeutics4.0681 of 5 stars$29.23+1.2%$46.83+60.2%+36.1%$2.04BN/A-7.7030Insider TradeMIRMMirum Pharmaceuticals4.0751 of 5 stars$42.39-0.1%$57.73+36.2%+34.8%$2.03B$307.03M-21.01140Positive News Related Companies and Tools Related Companies AMRX Competitors LBPH Competitors LGND Competitors GERN Competitors NAMS Competitors IDYA Competitors CNTA Competitors WVE Competitors AKRO Competitors MIRM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MLYS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
